Vaxcyte, Inc. (PCVX) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Vaxcyte, Inc. (PCVX:NASDAQ), powered by AI.

Current Price
$49.31
P/E Ratio
-8.8
Market Cap
6.7B
Sector
Healthcare
What is the Vaxcyte, Inc. stock price forecast?

Vaxcyte, Inc. is currently trading at $49.31. View real-time AI analysis on Alpha Lenz.

What is Vaxcyte, Inc. insider trading activity?

View the latest insider trading data for Vaxcyte, Inc. on Alpha Lenz.

What is Vaxcyte, Inc.'s P/E ratio?

Vaxcyte, Inc.'s P/E ratio is -8.8.

Vaxcyte, Inc.

NASDAQ · PCVX
$49.31-0.25(-0.50%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Vaxcyte, Inc.'s future dividend policy...
Alpha Chat Insight

Vaxcyte, Inc. trades at a P/E of -8.8 (undervalued) with modest ROE of -25.6%.

Ask for details

Company Overview

Vaxcyte Inc. is a biotechnology company focused on developing innovative vaccines for preventing infectious diseases. The primary objective of the company is to create safer and more effective vaccines using its proprietary cell-free protein synthesis platform, a groundbreaking technology that aims to enhance vaccine design and production efficiency. Vaxcyte’s developments are particularly significant in the pharmaceutical industry, as they target diseases with high unmet medical needs and those that pose significant global health challenges. By addressing vaccine efficacy and safety, Vaxcyte contributes to the broader health sector’s mission to improve public health outcomes. The company's efforts are crucial in advancing preventative healthcare measures, providing new solutions for vaccine-preventable diseases. As part of the larger biotechnology market, Vaxcyte Inc. plays a pivotal role in fostering innovation that could redefine standards for vaccine development, offering potential breakthroughs through its cutting-edge approaches.

CEOMr. Grant E. Pickering M.B.A.
SectorHealthcare
IndustryBiotechnology
Employees414

Company Statistics

FY 2025

Profile

$6.71BMarket Cap
$0.00Revenue
0.00Shares Out
414Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-8.75P/E
2.50P/B
N/AEV/Sales
-7.40EV/EBITDA
-9.42P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-23.54%ROA
-25.59%ROE
-28.36%ROIC

Financial Health

$173.96MCash & Cash Equivalents
$143.25MNet Debt
11.81%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Vaxcyte, Inc. (ticker: PCVX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 414 employees. Market cap is $6.7B.

The current price is $49.31 with a P/E ratio of -8.75x and P/B of 2.5x.

ROE is -25.59%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Vaxcyte, Inc. (PCVX) Stock Forecast 2026 $49.31 — Price, Financials & Analyst Targets | Alpha Lenz